{"_":"Pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma- evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC).","i":["ex vivo"]}
恶性胸膜间皮瘤（MPM）是一种罕见但侵袭性强的疾病，预后差且治疗选择有限。加压胸腔内气溶胶化疗（PITAC）已成为一种新型的胸腔内药物递送方法。本研究旨在通过模型研究顺铂的渗透特性，并评估影响药物渗透的操作参数，包括温度、药物浓度和胸膜屏障功能。此外，将PITAC与热灌注胸腔内化疗（HITOC）进行比较，后者是部分专科中心作为MPM多模式治疗概念组成部分所采用的治疗方式。我们在模型设置中研究了使用高压雾化器产生的气溶胶化顺铂的渗透深度和强度。我们逐步调整了潜在影响因素，包括温度、顺铂浓度和胸膜屏障功能，以评估最佳操作条件。最后，将PITAC与先前标准化的HITOC方法进行比较。42℃的温度、1 mg/mL的顺铂浓度以及预先去除胸膜，改善了化疗药物的渗透深度和强度。在临床相关实验条件下，气溶胶化顺铂应用显示出比HITOC更大的组织渗透。我们的临床前数据表明，PITAC可能是HITOC的可行替代方案，值得进一步临床研究。
Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with poor prognosis and limited treatment options. Pressurized intrathoracic aerosol chemotherapy (PITAC) has emerged as a novel approach for intrathoracic drug delivery. The aim of this study was to investigate cisplatin penetration characteristics and to evaluate procedural parameters influencing drug penetration, including temperature, drug concentration and pleural barrier function, in an model. In addition, PITAC was compared with hyperthermic intrathoracic chemotherapy (HITOC), a treatment modality applied in selected specialized centers as part of multimodal treatment concepts for MPM. We investigated the penetration depth and intensity of aerosolized cisplatin generated using a high-pressure nebulizer in an setting. Potential influencing factors, including temperature, cisplatin concentration and barrier function of the pleura, were gradually modified, as we sought to evaluate optimal procedural conditions. Finally, PITAC was compared with a previously standardized HITOC approach. A temperature of 42 ℃, a cisplatin concentration of 1 mg/mL, and prior removal of the pleura, improved the penetration depth and intensity of the chemotherapeutic agent. Under clinically relevant experimental conditions, aerosolized cisplatin application demonstrated greater tissue penetration compared to HITOC. Our preclinical data suggest that PITAC may be a viable alternative to HITOC and warrants further clinical investigation.
Katharina Flöthmann, Norman Zinne, Peter Braubach, Alina Meininger, Imke Becker, Nicole Ernst, et al. {"_":"Pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma- evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC).","i":["ex vivo"]}. Journal of thoracic disease. 2026; doi:10.21037/jtd-2026-1-0258.
Katharina Flöthmann, Norman Zinne, Peter Braubach, Alina Meininger, Imke Becker, Nicole Ernst, et al (2026). {"_":"Pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma- evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC).","i":["ex vivo"]}. Journal of thoracic disease. https://doi.org/10.21037/jtd-2026-1-0258
Katharina Flöthmann, Norman Zinne, Peter Braubach, Alina Meininger, Imke Becker, Nicole Ernst, et al. {"_":"Pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural mesothelioma- evaluation of optimal treatment conditions and comparison with hyperthermic intrathoracic chemotherapy (HITOC).","i":["ex vivo"]}[J]. Journal of thoracic disease, 2026 doi:10.21037/jtd-2026-1-0258.
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出